🥴
UBS cuts BioNTech price target by 43% saying pandemic trade premium is fading
While still maintaining BioNTech (NASDAQ:BNTX) at neutral, UBS has cut its price target to $170 from
免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。
点赞
举报
登录后可参与评论

暂无评论
🥴
免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。